Rapamycin modulates the eNOS vs. shear stress relationship

Cardiovascular Research

Volumn 78, Issue 1, 2008, Pages 123-129

  Cheng, Caroline ^a   Tempel, Dennie ^a   Oostlander, Angela ^a   Helderman, Frank ^a   Gijsen, Frank ^a   Wentzel, Jolanda ^a   Van Haperen, Rien ^a   Haitsma, David B ^a   Serruys, Patrick W ^a   Van Der Steen, Anton F W ^a   De Crom, Rini ^a   Krams, Rob ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atherosclerosis; C57BL6; Rapamycin; Shear stress

Indexed keywords

APOLIPOPROTEIN E; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENHANCED GREEN FLUORESCENT PROTEIN; NITRIC OXIDE SYNTHASE; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; BLOOD VESSEL; CHOLESTEROL INTAKE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SHEAR STRESS; VASODILATATION;

ANIMALS; APOLIPOPROTEINS E; CARDIOVASCULAR AGENTS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; GREEN FLUORESCENT PROTEINS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; NITRIC OXIDE SYNTHASE TYPE III; PULSATILE FLOW; RECOMBINANT FUSION PROTEINS; SIROLIMUS; STRESS, MECHANICAL;

EID: 41149103415     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm103     Document Type: Article

References (17)

1. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006;27:166-170.
2. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005;46:231-236.
3. Gijsen FJ, Oortman RM, Wentzel JJ, Schuurbiers JC, Tanabe K, Degertekin M et al. Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries. Am J Cardiol 2003;92:1325-1328.
4. Cheng C, de Crom R, van Haperen R, Krams R. In vivo induced changes in the shear stress pattern affect the expression and the intracellular localization of endothelial nitric oxide synthase. Blood 2005;106:3691-3698.
5. van Haperen R, Cheng C, Mees BM, van Deel E, de Waard M, van Damme LC et al. Functional expression of endothelial nitric oxide synthase fused to green fluorescent protein in transgenic mice. Am J Pathol 2003;163:1677-1686.
6. Carlier SG, van Damme LC, Blommerde CP, Wentzel JJ, van Langehove G, Verheye S et al. Augmentation of wall shear stress inhibits neointimal hyperplasia after stent implantation: inhibition through reduction of inflammation? Circulation 2003;107:2741-2746.
7. Gijsen FJ, van de Vosse FN, Janssen JD. Wall shear stress in backward-facing step flow of a red blood cell suspension. Biorheology 1998;35:263-279.
8. Gijsen FJ, Allanic E, van de Vosse FN, Janssen JD. The influence of the non-Newtonian properties of blood on the flow in large arteries: unsteady flow in a 90 degrees curved tube. J Biomech 1999;32:705-713.
9. Waksman R, Ajani AE, Pichard AD, Torguson R, Pinnow E, Canos D et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004;44:1386-1392.
10. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773- 1780.
11. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-2170.
12. Farb A, John M, Acampado E, Kolodgie FD, Prescott MF, Virmani R. Oral everolimus inhibits in-stent neointimal growth. Circulation 2002;106:2379-2384.
13. Ramzy D, Rao V, Tumiati LC, Xu N, Miriuka S, Delgado D et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006;114:I214-I219.
14. Naoum JJ, Zhang S, Woodside KJ, Song W, Guo Q, Belalcazar LM et al. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: differing effects of rapamycin and simvastatin. Surgery 2004;136:323-328.
15. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001;280:F193-F206.
16. Castro C, Campistol JM, Sancho D, Sanchez-Madrid F, Casals E, Andres V. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis 2004;172:31-38.
17. Elloso MM, Azrolan N, Sehgal SN, Hsu PL, Phiel KL, Kopec CA et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003;3:562-569.